RAPP - Rapport Therapeutics, Inc. Common Stock

RAPP - Rapport Therapeutics, Inc. Common Stock

https://www.rapportrx.com

Hold Momentum: Bearish

Recent News

Powered by Alpha Vantage

RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal

Zacks Commentary • 3 days ago • score: 0.25

Rapport Therapeutics stock jumps 62% in a week as mid-stage study of RAP-219 meets goals in drug-resistant epilepsy patients.

Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

GlobeNewswire • 3 days, 19 hours ago • score: -0.05

BOSTON and SAN DIEGO, Sept. 11, 2025 ( GLOBE NEWSWIRE ) -- Rapport Therapeutics, Inc. ( Nasdaq: RAPP ) ( "Rapport" or the "Company" ) , a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or ...

Rapport Announces Pricing of Public Offering of Common Stock - Rapport Therapeutics ( NASDAQ:RAPP )

Benzinga • 5 days, 14 hours ago • score: 0.09

BOSTON and SAN DIEGO, Sept. 09, 2025 ( GLOBE NEWSWIRE ) -- Rapport Therapeutics, Inc.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-09 (Snapshot)

None

52W High

$29.74

52W Low

$6.43

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

N/A

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

11.97

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

N/A

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

1.99

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

6.26%

Institutions (25–75% balanced)

106.26%

Shares Outstanding

36,497,900

Float

14,960,100

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

0

EPS (TTM)

1.20

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.29%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

3.0829

Previous

3.0078

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025